Longitudinal analysis within one hospital in sub-Saharan Africa over 20 years reveals repeated replacements of dominant clones of Klebsiella pneumoniae and stresses the importance to include temporal patterns for vaccine design considerations

*Eva Heinz^{1,2}, Oliver Pearse^{2,3}, Allan Zuza³, Sithembile Bilima³, Chisomo Msefula⁴, Patrick Musicha^{2,3}, Patriciah Siyabu⁵, Edith Tewesa⁵, Fabrice E Graf², Rebecca Lester^{3,6}, Samantha Lissauer^{3,7}, Jennifer Cornick^{3,7}, Joseph M Lewis^{2,3,7}, Kondwani Kawaza^{3,4}, Nicholas R Thomson^{8,9}, *Nicholas A Feasey^{2,3,10}

- 1. Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
- 2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

3. Malawi Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi

- 4. Kamuzu University of Health Sciences, Blantyre, Malawi
- 5. Queen Elizabeth Central Hospital, Blantyre, Malawi
- 6. Division of Infection & Immunity, University College London, UK

7. Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK

- 8. Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, UK
- 9. London School of Hygiene and Tropical Medicine, London, UK
- 10. School of Medicine, St Andrews University, UK

*Contact: eva.heinz@lstmed.ac.uk, Nicholas.feasey@lstmed.ac.uk

Keywords: AMR, Malawi, genome surveillance, healthcare-associated, nosocomial infections, surface antigens, neonatal infection, sepsis, capsular polysaccharide, ESKAPE

1 Abstract

Infections caused by multidrug-resistant gram-negative bacteria present a severe threat to 2 global public health. The WHO defines drug-resistant Klebsiella pneumoniae as a priority 3 4 pathogen for which alternative treatments are needed given the limited treatment options and 5 the rapid acquisition of novel resistance mechanisms by this species. Longitudinal descriptions of genomic epidemiology of Klebsiella pneumoniae can inform management 6 7 strategies but data from sub-Saharan Africa are lacking.

8 We present a longitudinal analysis of all invasive K. pneumoniae isolates from a single 9 hospital in Blantyre, Malawi, southern Africa, from 1998-2020, combining clinical data with 10 genome sequence analysis of the isolates. We show that after a dramatic increase in the 11 number of infections from 2016 K. pneumoniae becomes hyperendemic, driven by an increase 12 in neonatal infections. Genomic data show repeated waves of clonal expansion of different, 13 often ward-restricted, lineages, suggestive of hospital associated transmission. We describe 14 temporal trends in resistance and surface antigens, of relevance for vaccine development.

15 Our data highlight a clear need for new interventions to prevent rather than treat K. 16 pneumoniae infections in our setting. Whilst one option may be a vaccine, the majority of 17 cases could be avoided by an increased focus on and investment in infection prevention and 18 control measures, which would reduce all healthcare associated infections and not just one.

19

20 21

22

23 Background

The burden of deaths in children under the age of five, including those due to neonatal sepsis, 24 25 is especially high in low- and middle-income countries (LMICs)(1); and one of the main 26 pathogens causing these is Klebsiella pneumoniae (Kpn)(2). Until the last decade, Kpn was 27 typically readily treatable with beta-lactam antimicrobials, in particular third generation 28 cephalosporins (3GC). The effectiveness of 3GC is lost when these bacteria acquire 29 extended-spectrum beta-lactamase enzymes (ESBLs). For Kpn there has been a drastic 30 increase in 3GC-resistance by acquisition of ESBL enzyme-encoding plasmids; the proportion 31 of Kpn hospital isolates that are ESBL-producing increased from 12% to >90% in parts of sub-32 Saharan Africa (sSA) in the last decade(3). The main remaining treatment option are 33 carbapenems; these however are uncommonly available in sSA, rendering Kpn effectively 34 untreatable in large parts of Africa. This is particularly problematic for neonatal sepsis caused 35 by Kpn, and there is increasing evidence from large studies such as BARNARDS(2) and 36 CHAMPS(4) that the burden of disease caused by Kpn falls most heavily on this patient group. 37 Treatment options for neonates are even more limited than for other age groups as therapy 38 needs to be intravenous and some antimicrobial classes are contraindicated, however delay 39 in establishing appropriate therapy is even more dangerous.

40

41 The population structure of Kpn, similar to other opportunistic pathogens that thrive in the environment, is highly complex(5). Understanding long-term population trends of clinically 42 43 relevant lineages at both a local and global scale, and which antimicrobial resistance plasmids 44 and elements they encode, is potentially relevant to guiding treatment, infection prevention 45 strategies and vaccine development. However, few longitudinal studies of Kpn population 46 have been published so far, and the majority have come from collections established in high-47 income settings or South East Asia(6–10), whilst data from Africa and South America remain 48 sparse. Low-income countries in sub-Saharan Africa are particularly underrepresented in 49 'global' collections of pathogen genome data, despite often carrying the highest burden of 50 disease(2).

51

52 Whilst Kpn has a global distribution, there are clear geographical concentrations of dominant 53 lineages and resistance genes, likely reflecting local antimicrobial pressure, patient 54 populations, and a range of other determinants. Developing a more representative picture of 55 the global epidemiology of Kpn is relevant to the development of vaccines targeting Kpn, to 56 ensure that the lineages and associated LPS O-antigens and capsular polysaccharide antigens most prevalent in countries with the highest burden of disease are targeted. A better 57 58 understanding of the genomic epidemiology of Kpn in low-income countries is also crucial to 59 advocate for access to antimicrobials, in particular newer agents, which is often profoundly 60 limited by cost, leaving isolates that can be readily treated in high- or middle-income countries 61 de facto untreatable. Further, knowing at a facility level where problematic hotspots of 62 transmission are within a hospital setting can help focus infection prevention and control (IPC) efforts. 63

64

65 To address this urgent need for a better understanding of the Kpn population in sSA, we 66 performed whole-genome sequencing on all bloodstream isolates phenotypically identified as 67 Kpn from Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, which has 68 undertaken sentinel surveillance of bacteraemia and meningitis in partnership with the Malawi-69 Liverpool Wellcome Programme (MLW) since 1998(3). Our analyses include all isolates, 70 irrespective of resistance profile or patient demographic, from 1996 to 2020, with no change

71 in sampling strategy from 2000 - 2020. We report the shifts in resistance profile and population

structure over time and highlight the relevance to consider trends over time and not just total 72

73 numbers for considerations of new drug regiments or vaccine target selection.

74

75 Results

76 The QECH bloodstream isolate collection

77 QECH is the main referral hospital for the southern region of Malawi and the main hospital for 78 Blantyre, the second largest city of Malawi (population 800,024 at the 2018 census). It has 79 approximately 1,000 beds and receives around 10,000 adult medical and 30,000 paediatric 80 medical admissions per year. A quality assured diagnostic microbiology service was initially 81 implemented in partnership with MLW at QECH in 1998. Laboratory blood culture was initially 82 manual, and an automated system was implemented in 2000 (BacT/ALERT, Biomerieux). The 83 diagnostic microbiology service expanded to culture cerebrospinal fluid (CSF) from 2002. 84 During the study period, all adult and paediatric medical patients with suspected sepsis or meningitis were eligible for blood and/or CSF culture at the discretion of the admitting 85 86 physician, and where possible before the administration of antimicrobials. Bacterial isolates 87 were identified by standard techniques detailed in the methods.

88

89 At the start of the period, first-line treatment against bloodstream infections was crystal-90 penicillin and chloramphenicol although gentamicin was used in neonates instead of 91 chloramphenicol. This began to change with the introduction of the 3rd-generation 92 cephalosporin ceftriaxone from 2004, which was rapidly adopted as a first line agent by the 93 Department of [adult] Medicine and more slowly by the Department of Paediatrics, which 94 continues to use penicillin and gentamicin in the management of neonatal sepsis, as per WHO 95 guidelines(11).

96

97 Members of the order Enterobacterales including Kpn were identified by API biochemical 98 index (Biomerieux, France). Klebsiella pneumoniae is known to comprise a species complex 99 including Klebsiella pneumoniae subsp. pneumoniae as well as several closely related 100 species like K. variicola and K. quasipneumoniae and their respective subspecies(12). These 101 can only be identified to species complex level via API, and we therefore refer to all members 102 of the K. pneumoniae species complex as Kpn and specify when referring to specific 103 (sub)species (Fig 1A).

104

105 Dramatic increase in Kpn cases from 2016

The crude frequency of Kpn cases was high at the start of the period with 121 cases in 1998, 106 although this overlapped with a year of active surveillance of febrile adult patients(13) and we 107 108 thus focused longitudinal analyses from 2000 onwards. The number of cases from 2000 -2015 was stable with a mean of 44 cases per year (Fig 1A). This increased to a mean of 187 109 110 cases per year from 2016-2021 with a peak of 279 in 2019.

111

112 Neonatal infection with Kpn accounted for 39.3% of all Kpn infections, even though only 11.2% 113 of all blood cultures were taken from this patient group. The overall rate of Kpn isolation was 114 24.9 per 1000 blood cultures for neonates, 4.3 per 1000 blood cultures for other patients (rate 115 ratio of neonates vs non-neonates 5.11 [95% CI 4.66 - 5.61]). The increase in Kpn cases post 116 2016 was driven by an increase in neonatal infections (Fig S1A-1G); there were peaks in the 117 Kpn blood culture isolation rate in neonates in 2008, 2014 and 2017 which suggest outbreaks 118 or ongoing transmission on the neonatal unit (Fig 1B), and our genomic analyses further

- 119 support hospital transmission given the close genetic relationships of the respective isolates.
- Though the blood culture positivity rate was increased for most age groups in the period from 120
- 121 2016-2021, for neonates this increase was particularly marked (33.5 per 1000 blood cultures
- 122 in the period 2016-2021 compared to 15.4 per 1000 blood cultures in the period 1998-2015;
- 123 Fig S1A-1D). As well as the peak in neonatal cases, there was also a much smaller peak in
- 124 the adult age group, which shifted from the 30-35 year age group in the period from 1998-
- 125 2015 to the 35-40 year age group in the period from 2016-2021 (Fig S1E-1H).
- 126

127 Increase in Kpn numbers driven by temporally defined expansions of sequence types 128 (STs)

- 129 We retrieved 1313 isolates not previously sequenced from the QECH Kpn collection, 1302 of which could be recovered for growth and yielded enough DNA for sequencing; and 1156 of 130 131 these passed all quality control steps for further analysis (details see methods; Fig S2). In 132 addition, we included 217 samples from previously published studies of this collection(14-16), 133 resulting in 1373 sequenced genomes analysed in this study (Fig 1C).
- 134

135 The majority (1274/1373, 92.8%) belong to Klebsiella pneumoniae subsp. pneumoniae with 136 only very small proportions representing other (sub)species, including K. quasipnemoniae subsp. quasipneumoniae (10/1373, 0.7%), K. quasipneumoniae subsp. simillipneumoniae 137 (46/1373, 3.4%) and K. variicola subsp. variicola (43/1373, 3.1%). Based on phenotypic 138 139 microbiology data (Fig 1A and 1B) we observed a drastic increase in isolates from neonatal 140 infection in 2016/2017 which is reflected in our sequenced collection.

141

142 Assessing diversity of STs over time highlights that the increase in Kpn infections represents 143 repeated increase and subsequent decrease in numbers of different multilocus sequence 144 types (Fig 2A). Whilst the earlier years show a diverse composition of STs with small numbers of each (n < 15 total), the increase in total Kpn numbers is mainly driven by one or two major 145 146 STs, with these peaks spanning approximately 1.5 to 2 years each. We furthermore observe 147 that after the increase of isolates of the major STs, each of them reverts to their original very 148 low numbers (Fig 2A).

149

150 A previous study(15) highlighted an outbreak of ST340 across the neonatal unit which is 151 reflected here, where it comprises 31 out of 105 isolates in 2013 & 2014 (29.5%; Fig 2A). We 152 then see an increase of the numbers of ST14 (19 / 44 in 2015; 43.2%) which is present at a 153 lower proportion before and after this period; followed by an increase in ST25 (13 / 87 in 2016; 154 14.9%) which again is present at lower proportions before and after. The year 2017 then saw 155 a steep increase in Kpn infections overall; mainly driven by an expansion of ST39 which 156 comprises more than half the samples at the time (100/188 in 2017; 53.2%). This clone however again retreats back to low numbers, with a few lineages dominating, in particular 157 158 ST1552 (35 / 208 in 2018; 16.8%) and ST35 (40 / 208 in 2018; 19.2%). The year 2019 then sees another increase in ST14 (61 / 236 in 2019; 25.8%) as well as ST15 (30 / 236 in 2019; 159 160 12.7%), which is a known high-risk clone predominantly found in South East Asian collections 161 where it has been linked to an early spread of carbapenem resistances via blaNDM 162 genes(17,18).

163

164 Isolation of Kpn from neonatal and paediatric wards account for observed changes, 165 whilst adult infections remain stable over time

166 The patterns over time differ significantly between wards (Fig 2B), suggesting the increase in Kpn infections could represent a pattern of repeated ward-specific outbreaks, rather than a 167 168 generalised increase across all wards (Fig 2B). This pattern of ward-focused increases in isolate numbers was repeatedly observed on the Chatinkha neonatal unit and the surgical 169 PICU/HDU, where most of the changes in numbers of isolates occur. An indication of local 170 171 outbreaks is further supported by analysing the major STs, which increase at defined times in 172 specific wards (Fig 2B and 2C; Fig S3). To investigate the impact of closely related isolates 173 (<5 core SNP distance) that are likely within-hospital transmissions on the number of infections 174 overall, we analysed a core genome tree for each of the three species and identified closest-175 neighbour SNP distances in a root-to-tip approach(19) (Fig 3). This highlighted that most 176 highly clonal lineages (defined as <5 SNPs) are derived from K. pneumoniae subsp. pneumoniae (Fig 3A) representing 402 of 1165 isolates as a conservative estimate based on 177 178 whole-species analyses, with 43% of the K. quasipneumoniae subsp. similipneumoniae (20 179 of the 46 isolates in 6 lineages, Fig 3B) and 25% of the K. variicola isolates (10 of the 40 isolates of this species, Fig 3C); and no <5 SNP related isolates of K. quasipneumoniae subsp. 180 181 quasipneumoniae.

182

183 Despite removing the single-isolate STs for this analysis, our dataset still contains a high number of K. pneumoniae subsp. pneumoniae STs, which results in a highly diverse dataset. 184 As this diversity has potential to impact on tree resolution depending on reference used(20), 185 we investigated three key STs in more detail. We focused on ST35, ST39, and the closely 186 187 related ST14 and 15 together, whose pattern of accumulation in a ward and year strongly 188 indicates multiple hospital-associated transmissions (Fig S3), in more detail by mapping 189 against strain-specific reference genomes (Fig 3A). ST39 and ST35 are two key STs when 190 considering the per-year breakdown of isolates per ward for the neonatal unit (Chatinka; Fig 191 S3); whilst ST14 and ST15 were identified in high numbers in the PICU/HDU in the paediatric surgical ward (Fig S3). Here, we can observe that 77% of the isolates (51/55 ST35, 110/136 192 193 ST39, 182/254 ST14-15) have their nearest neighbour within the threshold of 5 SNPs; 194 representing 100% (17/17) of ST35 and 88.9% (80/90) of ST39 from Chatinka and 88% 195 (57/65) ST14 and 15 from the PICU/HDU (Fig 3A). This high relatedness of isolates strongly 196 supports within ward transmission and the argument that Kpn is a healthcare associated 197 cause of neonatal sepsis. As patients are regularly transferred from Chatinkha to the 198 PICU/HDU if surgical procedure is required, these wards are furthermore already linked by a 199 clear transmission path via patients, and several potential between-ward transmission events 200 are indicated in particular in ST35 and ST14/15 (Fig 3D, F).

201

202 Over the period from 2015-2018 there was an increased focus on performing blood cultures 203 to ensure every neonate on Chatinkha nursery that met the clinical criteria for suspected 204 neonatal sepsis was included, which may explain some of the large increase in Kpn cases in 205 2017 on the nursery. Establishing optimal IPC has been an ongoing challenge(21); 206 specifically, handwashing has been difficult due to intermittent water supply and a lack of 207 access to soap or hand sanitiser and there are limited numbers of cots, so neonates have 208 often shared them. In response to the large increase in Kpn cases there was renewed focus 209 on IPC; hand sanitizer and soap procurement was prioritized, deep cleans of the ward 210 environment were performed regularly, there was increased cleaning of ward surfaces, ward 211 traffic was limited, wooden cots are being replaced with easier to clean plastic ones, the 212 number of neonates sharing a cot was reduced and oxygen delivery devices are being 213 replaced with single use items.

214

Antimicrobial resistance and implications for treatment 215

Phenotypic resistance profiles of the strains, where available, mirrors the very concerning 216 217 trends reported previously for Kpn in QECH(3) (Fig S4, Table S4). Resistance against the frontline treatments is widespread; a particular concern is a high proportion of isolates with 218 219 ceftriaxone, gentamicin and cotrimoxazole resistance from 2012 onwards with very little 220 change over time (Fig S4A-C; >75% of tested isolates were resistant to these agents each 221 year 2012 - 2020). We notice some variation in co-amoxiclav (augmentin: amoxicillin + 222 clavulanic acid) susceptibility profiles but from 2019 again show >75% of tested isolates as 223 resistant (Fig S4A). Importantly, we notice that a trend of increased numbers of 224 chloramphenicol susceptible isolates (Fig 4B, Fig S4G), which has previously reported in Malawi(3), is also explicit in our Kpn collection in particular in recent isolates (38.7%, 51.5%, 225 226 72.2% isolates sensitive for 2018-2020). Presence of catA1 or catA2 agree well with 227 phenotypic resistance whereas presence of *catB4* did not as shown in Fig 4B; where we see 228 a large number of isolates with sensitive phenotype, no catA1/2 but catB4, whereas only a 229 small fraction of isolates has resistant phenotype, no catA1/2 but catB4 where we hypothesize 230 a different mechanism is likely driving the resistant phenotype. For isolates with resistant 231 phenotype and encoding both catA1/2 and catB4 the resistance is presumed to be driven by 232 catA1/2. This agrees with catB4 representing a non-functional truncated variant of catB3 as 233 was recently reported. We furthermore note a sensitivity of 50% or higher in the majority of 234 years measured in ciprofloxacin (6/9 years from 2012 to 2020, including 2017, 2018 and 2020; 235 Fig S4E, Table S4), which together with chloramphenicol thus represent two antimicrobials 236 that might thus be valid treatment options.

237

238 Resistance to 3GC was widespread (83% resistance to cefpodoxime/ceftriaxone by 2020; Fig. 239 S4A) and almost exclusively driven by acquisition of the *bla_{CTX-M-15}* gene, which continuously 240 outcompetes other ESBL-encoding genes that are occasionally present in the Kpn population. 241 but which are only sporadically detected (Fig 4A, Table S2). The number of plasmid replicons 242 per isolate stabilised after the first increase in numbers around 2015, highlighting that a few large AMR plasmids are likely responsible for the majority of AMR-isolates (Fig S5C, Fig S6A, 243 244 Table S3). Strains with a moderate number of plasmid replicons dominate the population (0-245 5) and this remains stable over time, with only a small number of isolates with more than five 246 plasmid replicons associated that remains at similar numbers over time (Fig S6A). This 247 indicates that the change to a predominantly ESBL⁺ population was the key event, with the 248 population then remaining stable over time with respect to plasmid diversity and numbers of 249 resistance genes (Fig S6B).

250

251 Carbapenem resistance genes are still only rarely observed; we identified two samples encoding for *bla_{NDM-1}*; one in a ST39 in 2016 and one in a ST45 in 2019, perhaps unsurprisingly 252 253 as carbapenem usage is still comparatively unusual. We also investigated resistances against 254 other potential alternative treatment options colistin, fosfomycin and tigecycline. Resistance 255 to these agents are all at low levels, with only one acquired fosfomycin resistance gene 256 detected (fosA) and none against colistin or tigecycline predicted in our dataset, and one isolate with predicted mutations that can confer resistance to colisin (*pmrB*), indicating that 257 these might be viable alternatives for ESBL⁺ infections at QECH, although tigecycline is 258 259 contraindicated in children under 8y (Table S2) and neither agent may not be ideal treatments 260 for bacteraemia(22,23). Tigecycline resistance is often conferred by upregulation of transport 261 proteins and thus challenging to predict and has also been observed during within-patient

262 evolution(24–26); we could however not detect the described plasmid-derived antimicrobial resistance genes *tetX* in our collection(27). 263

264

Based on AMR phenotype identified by disc diffusion, amikacin remains a viable alternative 265 to gentamicin, although there are concerns over blood brain barrier penetration in cases of 266 267 meningitis and renal toxicity in settings where therapeutic drug monitoring is not possible. 268 Phenotypic data are corroborated by a more detailed analysis of the aminoglycoside AMR 269 genes (Fig 4C and 4D). In total 90.5% of all isolates (1243/1373) are predicted to encode one 270 or more aminoglycoside resistance genes, however, the majority are predicted to confer 271 resistance to streptomycin (ANT3) and gentamicin (AAC(3)-II; ANT(2")-I; Fig 4D). Only a 272 fraction of these strains (43.2%, 593/1373) encoded one of the genes predicted to confer 273 resistance against amikacin (AAC(6')-I; Fig 4C). Aminoglycoside resistance is known to be 274 challenging to predict(28); whilst phenotypic gentamicin resistance testing matches very well 275 with the predicted profile based on acquired genes, the presence of AAC(6')-I does not by 276 itself confer resistance in a large number of isolates, with only 12 isolates encoding for either 277 of these, representing 2%, actually showed a resistant phenotype (Fig 4D; Table S4).

278

279 Potential vaccine target stability

280 The Kpn polysaccharide antigens are of high interest as vaccine targets; in particular the large capsular antigen. As expected, we observed a very high number of different K-loci (90 281 282 predicted), as well as a diverse set of O-loci (15 predicted), the latter are known to be far less 283 diverse in Kpn(29). Recent findings furthermore showed that wbbZ, encoded on the 284 chromosome outside the O-locus, contributes to the diversity of the O-Ag structure displayed 285 by Kpn and thus two isolates with the same O-locus can still result in different O-types based 286 on the presence or absence of this gene. Immunologically relevant differences in O-Ag thus 287 requires the prediction of the O-Ag locus and *wbbZ*(30), so we added this to our O-Ag type predictions (Fig S7A-D) where we thus distinguish between O1a and O1b as described by 288 289 Kelly et al(30). Reflecting the trend observed with the ST types, we observe temporal variation 290 in prevalence of O-types and K-types (Fig 5A and 5D, Fig S7A). The non-ESBL population 291 again displays a much greater diversity for both types of antigen (Fig 5B and 5E, Fig S7B), 292 whilst the ESBL population is more biased towards dominant O- and K-types (Fig 5C and 5F, 293 Fig S7C).

294

295 Beyond the dominant O1b (821/1373; 59.8%) and O2afg (184/1373; 13.4%) predicted O-296 antigen types, the infrequently observed type O4 comprises a substantial fraction of isolates 297 (90/1373; 6.6%); and 35 isolates have a prediction accuracy as "Low" or "None" which can 298 indicate either low assembly quality or novel O-Ag loci and types. In addition, we note two 299 isolates with unknown O-Ag locus encoding for additional wbbY and wbbZ genes, indicating 300 that more variation might be within possibly novel O-Ag loci depending on additional enzymes 301 encoded in the chromosomal backbone (Table S5). We furthermore note 8 isolates with 302 O1/O2 loci encoding for only *wbbZ* (not *wbbY*); whilst the recent work showed no structural 303 differences in the O-Ag if wbbZ alone was added, we cannot exclude other carbohydrate 304 enzymes on the chromosomes of our isolates that might lead to additional different structures 305 if combined with wbbZ (Table S5). Of relevance, we also observe variation of O- and K-type 306 combinations within the same sequence type (Fig 5G and H, Fig S7D) and with each other 307 (Fig 5I, Fig S7E).

308

309 Considering hypothetical vaccine strategies and constructs, an efficacious maternally 310 administered quadrivalent O-antigen based vaccine (O1a, O1b, O2afg, O4; including O1a as 311 O1b-enconding isolates can switch between O1a and O1b(30)) would be expected to protect against up to 89% of cases of neonatal sepsis in Blantyre (345/388), whereas a K-antigen 312 based vaccine would require 22 K-antigens to be represented to protect against an equal 313 314 number of cases of neonatal sepsis when taking the entire timespan of our study into account 315 (KL10, KL102, KL103, KL104, KL106, KL108, KL117, KL142, KL15, KL16, KL17, KL19, KL2, 316 KL23, KL25, KL30, KL43, KL48, KL51, KL52, KL62, KL9); a quadrivalent K-antigen based 317 vaccine (KL2, KL25, KL30, KL102) would cover 58% (198/388) of cases. We furthermore 318 observe no regular cycling between a specific set of K-types, but rather that different K-types 319 regularly emerge associated with major clones (Fig 5). Given current knowledge of >180 predicted K-types(31) and >70 determined structures so far(32-34) (likely an 320 321 underestimation), and the propensity of the K-locus to recombine, it will be very challenging 322 to predict how long a K-type vaccine would remain effective.

323

324 Trends of resistance vs virulence determinants

325 Whilst most Kpn isolates are opportunistic pathogens with poorly understood virulence 326 profiles, the hypermucoid phenotype is a known virulence determinant arising from hyperproduction of capsule and causing a different clinical infection type, i.e. liver abscess 327 328 and meningitis in otherwise healthy individuals, often progressing very rapidly and with poor 329 prognosis. The capsule hyperproduction is usually driven by acquisition of a virulence plasmid 330 encoding for the capsule polysaccharide upregulation factor rmpA2 as well as several 331 siderophore systems (aerobactin, salmochelin, colistin) that enable iron scavenging. This 332 phenotype is of particular concern given the recent convergence of hypervirulent with 333 multidrug resistant isolates. Whilst we note hypervirulent isolates present (defined here as 334 kleborate virulence score >1, i.e. encoding virulence factors in addition to the often 335 chromosomal versiniabactin) from the very early sampling times on in our collection (Fig 336 S8A,B, Fig S5B), these remain sporadic; in contrast to multidrug resistant isolates (Fig S8C,D 337 Figwhich are absent at these early sampling times but rapidly become the majority of isolates 338 from 2007/8 onwards (Fig S8D). Whilst we note a total number of >10 isolates for both ST86 339 and ST268, two STs carrying the rmpA2 gene and widely observed as hypervirulent 340 phenotypes, these occur in different years and wards, highlighting that hospital-derived 341 transmission is highly unlikely (Fig S8B). Whilst it is of concern that we observe some of these 342 potentially hypervirulent isolates (encoding for *rmpA2*) also encoding an ESBL gene (22 total; 343 9 of these ST86, no ST268) there seems to be no selective advantage; the first isolate carrying 344 this combination is observed in 2010 but a maximum of 4 isolates per year are observed until 345 2020. This small number of putative hypervirulent isolates is in accordance not only with 346 bloodstream isolates in general but also with a study comparing carriage with infectious 347 isolates from adults in Blantyre, where only a very small number of isolates encoding virulence 348 determinants were identified, all of them in infectious isolates(35,36).

349

350 Discussion

351 Neonatal sepsis is responsible for a high proportion of deaths in children under 5 in sSA, with 352 Klebsiella by now being both the most prevalent gram-negative pathogen and increasingly 353 hard to treat. We have analysed a longitudinal collection of routine diagnostics invasive 354 (bloodstream and CSF) isolates of Kpn spanning from 1998 – 2020, during which time AMR 355 increased drastically. We determined longitudinal patterns of patient demographics, Kpn 356 population trends, vaccine targets, resistance elements and remaining treatment options. This

357 exceptional resource, not only for sSA but also world-wide, enables us to understand the dynamics of Kpn over an exceptionally long time scale where the sampling was not biased 358 359 towards resistance types. In particular, it allows us to see the dynamics before, during, and after the significant expansion of ESBL producing Kpn at maximum resolution; and highlights 360 the need to consider not only major types based on total numbers but the temporal dynamics 361 362 of vaccine targets such as cell surface polysaccharides.

363

364 Kpn initially showed a bimodal age distribution in patients at QECH(3) and there were 365 concerns that increasing life expectancy would lead to a higher number of adult infections; 366 however, this trend has yet to be seen, and adult bloodstream infections were significantly 367 reduced overall following the widespread distribution of antiretroviral therapy(37). The stark 368 increase in infections from 2016 onwards is almost exclusively seen in neonates and children 369 where ward-restricted clonal expansions that are subsequently replaced with other successful 370 clones. This suggests that context appropriate, effective, scalable infection prevention and 371 control (IPC) targeted towards the most vulnerable patient groups in the hospital and a better 372 understanding of Kpn transmission routes and reservoirs would prevent a large proportion of 373 the cases caused by Klebsiella bloodstream infection. Such approaches have the potential to 374 protect vulnerable babies against all healthcare associated infections rather than just one 375 pathogen and are available now, unlike a vaccine strategy that will take years to develop and 376 implement without guarantee for success.

377

378 The main sequence types in our study were ST39, ST14 and ST15. While ST39 and ST14 379 are not necessarily the most prevalent ones observed globally, ST15 is widely reported in 380 SouthEast Asia causing clonal outbreaks whereas it showed a different pattern in our setting 381 driving smaller expansions but also as a lot of sporadic isolates occurring over time. This 382 highlights the need for more data from sSA to understand the complex diversity of this 383 organism in high-risk areas, as not only the ST composition, but also their patterns, differ 384 between settings. The two key insights we gain from the population pattern is that the lineages 385 continue to replace each other as the dominant clone over longer time periods, and that in our 386 setting, this expansion is mainly driven by an increase in cases in neonatal patients. Most of 387 the major sequence types are present at a steady, much lower proportion, before and after 388 their respective clonal expansions, emphasizing the relevance of understanding what leads to 389 the wave-like pattern of clonal expansions in Kpn populations.

390

391 This temporal variability also favours prioritisation of IPC strategies to prevent the introduction 392 of new lineages. It may be that increased IPC efforts in response to ward outbreaks contribute to or are the single cause for the sudden stops of clonal expansions. We have little 393 394 understanding of the ability of Kpn to survive on abiotic surfaces, which represents one of the 395 key differences between HIC and LMIC settings, as the latter often use wooden furniture and 396 bristled plastic tubing due to limited resources, which might lead to different Kpn lineages 397 being successful. A similar question remains open regarding agents used for disinfection, as 398 resource-limited settings often rely on basic soap agents and use unsafe water, whilst HIC 399 routinely use industrially produced, quality controlled disinfectants.

400

401 Our data allow insight into AMR patterns in our setting. Ceftriaxone resistance, almost 402 exclusively due to the ESBL-encoding bla_{CTX-M-15}, is widespread. Whilst carbapenems are 403 rarely available and resistance is already emerging (38,39), several treatment options are still 404 viable, such as amikacin. Our analysis also emphasizes again that aminoglycoside resistance

405 is notoriously hard to predict and might be impacted by the genetic background (for example 406 efflux pumps) and not only acquired resistance genes, and should therefore at this stage not 407 be ruled out based on genomic data but confirmed via phenotyping. Most isolates were 408 phenotypically resistant to gentamicin; whether this is consequent on the predicted resistance 409 genes, or whether other mechanisms drive this resistance is important to determine to improve 410 the value of genotypic predictions for aminoglycosides. It will remain to be further investigated 411 whether this is due to other interfering genes or low expression of the resistance gene and 412 might be an indication of heteroresistance in the population which needs to be carefully 413 considered(40). We furthermore observe a trend in re-emergence of chloramphenicol 414 sensitivity, putatively in part driven by the spread of a non-functional CAT copy. Continuing to 415 monitor re-emergence of susceptibility to agents no longer in use is of high relevance to allow 416 timely re-introduction of drugs and can give us insights into the potential of rotating 417 antimicrobial regiments over longer time spans to allow sensitivity to re-emerge.

418

419 There was little resistance predicted and observed to colistin, a last-line treatment option, in 420 QECH Kpn isolates. Especially the lack of mobile resistance elements is encouraging, but 421 also stresses the urgent need for better management of animal health as colistin is widely 422 used, knowingly and as part of food products farmers are not necessarily aware of, in the 423 increasing mid-size farming industry(41). Another exciting new development are initial results 424 of combining fosfomycin and flomoxef(42); we observe only sporadic fosfomycin resistance 425 mechanisms and very little spread of *ampC* genes, the only non-carbapenemases that would 426 deactivate flomoxef, although we note that there are also counterindications for fosfomycin 427 use in invasive infections.

428

429 As extensively resistant bacterial pathogens emerge and spread, there is an increasing 430 urgency to develop vaccines to break the arms race between new antimicrobials and new 431 resistance mechanisms. In this case there is interest in developing maternally administered 432 Klebsiella vaccines to prevent neonatal sepsis. A target of high interest are the extracellular 433 polysaccharides that can be typed based on their respective operons, which are assigned 434 different K-types (capsular antigen) and O-types (the lipopolysaccharide O-antigen chain). 435 The K-antigen shows a very high diversity; and whilst we can identify several dominant types 436 in our study, the long timeframe of our study highlights the importance of considering the 437 dynamic nature of K-antigens when considering vaccine design. Here, temporal fluctuations 438 detected just in Blantyre strongly suggest that a K-type vaccine would become ineffective very 439 rapidly given the frequent changes in dominant K-type, which might be driven by phage 440 pressure in the environment and thus highly unpredictable. It is also unclear if successful 441 vaccination against the major polysaccharide types would lead to a degree of cross protection 442 against non-targeted types or whether lack of such cross protection would facilitate rapid 443 emergence of infections caused by vaccine escape lineages. 444

445 In contrast, there are far fewer O-antigen types, making this a more attractive target. Recent 446 efforts have compared several large datasets with O- and K-typing either determined by PCR 447 or WGS(43); and identified that a conjugate vaccine targeting O1v1/2 (~serotype O1)(31), 448 O2v2 (~serotype O2afg)(31) and O3b (~serotype O3b)(31) has the potential to prevent the majority (>70%) of cases of Kpn-BSI. For the most at-risk population in our setting, the 449 450 neonates, this would cover 87% of cases (338/388) assuming O1a and O1b were included 451 into O1 and no other subtypes were discovered(30); importantly it would however not have 452 prevented the ST340 outbreak in the neonatal unit previously described(15) (O4). It thus

453 seems of relevance to consider including the currently low-abundance O-antigens as well, in 454 particular given the interchangeability for O-types within the same STs. Reports from other 455 highly understudied settings also report other main O-types in hospital isolates, e.g. O5 in a study in Pakistan(17,44) or a diversity of O-types in the Caribbean where this O-Ag vaccine 456 457 would only cover 62% (162/260) (45). Selection pressure might not directly drive evolution 458 given that Kpn is not human restricted but could likely select for strains with currently less 459 abundant O-types to increase in prevalence. Further, there remains an open question of how 460 accessible the O-antigens are to antibodies, which a recent study calls into question(46); we 461 currently have very limited understanding what drives the extent of capsule expression per 462 cell in non-hypermucoid isolates and how different stages of the infection impact this. It is 463 known from *in vitro* studies that capsule expression even in the same experimental setting can 464 differ widely within clonal lineages, which also impacts the bacterial ability to escape the 465 complement system(47).

466

467 Our data, and the recent identification of a novel form of the long-studied O1 antigen type(30,48–50), highlights that we have very little understanding of the relevance of the O-468 469 and K-types on the success of Kpn lineages, whether any additional genes on the 470 chromosomal backbone can further modify the structures and lead to different serotypes with 471 the same O-locus, as well as whether any O-/K-combinations are more or less favourable. 472 Closing such knowledge gaps will be central to design of vaccines as we also have little 473 understanding for the propensity of sequence type combinations with specific vaccine target 474 serotypes such as capsule or O-antigen. A more solid understanding of O-/K-type variations, 475 both regarding their biochemistry and whether they contribute to epidemiological success, is 476 crucial given the high interest to use these as targets for maternally administered vaccines 477 against neonatal sepsis.

478

479 This highlights that we have very little understanding of the relevance of the O- and K-types 480 on the success of Kpn lineages, whether any additional genes on the chromosomal backbone 481 can further modify the structures and lead to different serotypes with the same o-locus, as well 482 as whether any O-/K-combinations are more or less favourable. A more solid understanding 483 of O-/K-type variations, both regarding their biochemistry and whether they contribute to 484 epidemiological success, is crucial given the high interest to use these as targets for 485 maternally administered vaccines against neonatal sepsis.

486 Conclusions 487

In summary, our study provides a unique insight into long-term patterns of Kpn hospital 488 489 isolates from a low-income setting, spanning across a time period where the number of MDR 490 and ESBL producing infections increased rapidly across the globe. We show that whilst STs 491 known as high-risk in other settings are common, these do not always show similar success 492 in different settings; and we observe a significant numbers of isolates from otherwise rarely 493 observed STs, causing hospital infections. This again emphasizes the importance of including 494 the relevant settings into studies aiming to identify treatment or vaccine targets as we currently 495 have poor understanding of what makes an ST a high-risk lineage in each setting at a given 496 time. Our data also emphasizes the urgent need to consider temporal variation when 497 considering treatment or vaccine targets, as some of the main vaccine targets show strong 498 temporal fluctuations; the most prevalent type now circulating is unlikely to cause the next 499 outbreak. The close relatedness of isolates from the same ward in the same time frame 500 strongly indicate that the majority of infections are hospital-acquired, so whilst vaccine

501 development and alternative treatment options are highly relevant; at this stage, focused 502 efforts to improve IPC are key to reducing Kpn disease burden now(21).

503

504 **Methods**

Isolate collection 505

506 QECH is a government run tertiary referral centre for the southern region of Malawi, which 507 provides free care at the point of delivery. It serves a population of 800,000 for the area of 508 urban Blantyre (Malawi census 2018). There are adult and paediatric A&Es, medical and 509 surgical wards. There is a tertiary neonatal unit on site and a separate paediatric surgical hospital which opened in 2017 (Figure 2C; PICU, Paediatric HDU, Paediatric surgical ward). 510

511

512 Microbiological sampling and processing

513 Routine, (ISO15189 accredited since 2019) diagnostic blood culture services have been 514 provided to the medical and paediatric wards by the Malawi-Liverpool-Wellcome Programme 515 since 2000. For adults 7-10mL of blood were collected from all patients admitted to the hospital 516 with fever (axillary temperature >37.5°C) or clinical suspicion of sepsis, severe sepsis, or 517 septic shock. Sepsis, severe sepsis, or septic shock were suspected in patients with 518 tachycardia (\geq 90 beats per minute), hypotension (systolic blood pressure <90 mm Hg), 519 tachypnoea (respiratory rate >20 per minute), or delirium. 3–10 mL of blood was taken from 520 children with non-focal febrile illness who tested negative for malaria, who were severely ill 521 with suspected sepsis, or who failed initial malaria treatment and remained febrile. For adults 522 and children with clinical suspicion of meningitis (temperature >37.5°C with seizures, 523 headache, abnormal behaviour or meningism) a lumbar puncture was also performed and the 524 sample sent for CSF analysis. For neonates with clinical signs of sepsis or meningitis 525 (temperature >37.5°C, or other signs of clinical deterioration such as reduced activity, 526 increasing work of breathing or respiratory rate >60, heart rate >180 or <100, and unexplained 527 seizures) a blood culture and CSF sample was collected. Afebrile patients were unlikely to 528 have had blood or CSF cultures unless the clinical suspicion for sepsis or meningitis was high.

529

530 For blood cultures, samples were collected using aseptic methods and inoculated into a single 531 aerobic bottle (BacT/Alert, bioMérieux, Marcy-L'Etoile, France). These were incubated using 532 the automated BacT/Alert system (bioMérieux, France) since 2000. Before which, they were 533 cultured manually. Samples that flagged positive were Gram stained and Gram-negative 534 bacilli are identified by Analytical Profile Index (Biomérieux). CSF samples were processed 535 for cell count and biochemistry before manual culture. Antimicrobial susceptibility testing was 536 determined by the disc diffusion method (Oxoid, United Kingdom) using AST breakpoints that were current at the time, initially following the relevant version of the British Society of 537 538 Antimicrobial Chemotherapy's guidelines until 2018, after which time EUCAST methods and 539 breakpoints were introduced. Organisms which showed reduced inhibition when exposed to 540 Ceftriaxone 30mg discs, Ceftriaxone 5mg discs, or Cefpodoxime 10mg discs were classified 541 as resistant to Ceftriaxone. Intermediate isolates were classified as resistant to ceftriaxone. 542 Details for the identification of other organisms are described elsewhere(3). Klebsiella 543 pneumoniae isolates were stored at -80°C on microbank beads.

544

545 Whole genome sequencing and QC

546 All Klebsiella pneumoniae isolates that could be recovered from the start of the MLW archive 547 to April 2020 were thawed and incubated on MaConkey's media for 18-24 hours at 37°C. 548 Plates with pure growth then had a single colony pick taken and inoculated into 15 ml of medRxiv preprint doi: https://doi.org/10.1101/2023.09.26.23296137; this version posted October 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

549 buffered peptone water for 18-24 hours at 37°C. These samples were then centrifuged and the supernatant was discarded. The pellet was then resuspended in buffer and the DNA was 550 551 extracted using the QIAsymphony machine and QIAsymphony DSP kit with onboard lysis, according to the manufacturer's instructions. Quality control was done using Qubit and 552 samples with a DNA volume of less than 200ng were repeated. DNA was sequenced at the 553 554 Wellcome Sanger Institute on the Illumina HiSeg X10 instrument (Illumina Inc., United States) 555 to produce 150 bp paired end reads.

556

557 Eleven out of 1313 samples failed the Sanger-internal sequencing threshold for minimum 558 coverage for assemblies and were thus removed from further analyses. Quality control on all 559 remaining isolates was performed using species confirmation via Kraken v0.10.6(51) to 560 identify contaminants (incorrect species). Any species assignment other than Klebsiella 561 pneumoniae, Klebsiella variicola, unclassified and synthetic construct were considered 562 contaminants; the latter two categories frequently derive from plasmid sequences in our 563 experience. All isolates with higher than 10% of other species were removed as contaminated (Fig S2A). Similarly, isolates with a ratio of heterozygous SNPs over 5% were removed as 564 565 likely contaminated by a related strain (Fig S2B). Further quality control used the assemblies, 566 where all isolates resulting in more than 1000 contigs were removed as likely contaminated by other species or strains, or of very low quality (Fig S2C). De novo assembly of the remaining 567 1156 genome sequences was performed using SPAdes v3.14.0(52) incorporated into the 568 569 bacterial genome assembly pipeline described previously(53). Annotation of all assemblies 570 was performed using prokka(54) v1.14.5.

571

572 Genome analyses and phylogenetics

573 For comparative analyses, isolates from recent studies at QECH were included, as they are 574 part of the bloodstream collection(14–16). Details of all sequences used in the analyses are 575 given in supplementary table 1. Resistance gene prediction and plasmid replicon types were 576 performed using ariba(55) (v2.14.6) and the srst2-argannot(56,57), CARD(58) and 577 plasmidfinder(59) databases (download date 14.02.2022). To assess aminoglycoside resistance; ANT3 is by ariba as AacAad AGly, AadA4 5 AGly, AadA AGly, AadA AGly 2, 578 579 AphA6 AGly; AAC(3)-II is grouped by ariba as Aac3 IIa AGly; ANT(2")-I is grouped by ariba 580 as AadB AGly and AAC(6')-I is grouped by ariba as AacAad AGly 3.

581

582 Prediction of sequence types, (sub)species and *Klebsiella*-specific virulence factors were 583 performed using kleborate v2.1.0(60) and the -r setting; the results are given for all isolates 584 in Table S1. O- and K-types were predicted with kaptive(31) (v2.0.6) which incorporates Oloci as well as O-serotype prediction(29,31,61); and we added an additional option of wbbZ 585 586 as extra gene to distinguish between O1a (O1/O2 + wbbY, no wbbZ) and O1b (O1/O2 + wbbY 587 + wbbZ) as described recently(30), adding wbbZ as implemented in kaptive versions before 588 v2(61) and expanding the .logic file to distinguish O1a/b.

589

590 Core genome SNPs for K. pneumoniae subsp. pneumoniae isolates were determined using 591 snippy(62) (v4.6.0; https://github.com/tseemann/snippy) with the Klebsiella pneumoniae 592 subsp. pneumoniae NTUH-K2044 genome (AP006725.1)(63) as reference. Recombinant 593 regions were removed using gubbins(64) (v3.2.1) and the FastTree(65) option ('-tree-builder 594 fasttree'), given the very high number of samples, as implemented in gubbins; and only 595 isolates from sequence types with more than one isolate in our dataset were included in the 596 analysis to further reduce compute time. The same strategy was used for K. quasipneumoniae

597 and K. variicola using strains ATCC 700603 (CP029597.1)(66) and At-22 (CP001891.1)(67) 598 as reference, respectively, where all isolates were included and default options for gubbins 599 were used (RaxML for tree generation, given the much smaller sample numbers). A snp-only 600 alignment was generated from the recombination-free gubbins output using snp-sites(68) v2.5.1 with the -c option (selecting for ACGT-only) for K. quasipneumoniae and K. variicola; 601 602 for K. pneumoniae subsp. pneumoniae, given the high variation of isolates, the -c option was 603 too stringent (resulting in a <200 bp alignment) and we thus used snp-sites to isolate all snps 604 but without selecting for ACGT-only sites.

605

The snp-only alignments were used as input for iqtree(69) (v1.6.12), the number of constant 606 607 sites was determined with snp-sites -C function from the original full alignment and provided 608 to the '-fconst x,x,x,x' igtree function. The model was determined with the integrated 609 ModelFinder(70) function '-m TEST' resulting in GTR+F+I+G4, GTR+F+I+G4, TVM+F+I+G4, 610 for the alignments from K. pneumoniae, K. quasipneumoniae and K. variicola, resp. We set 'keep-ident' to keep identical data and '-bb 1000' for 1000 ultrafast bootstrap replicates. The 611 resulting trees were then adjusted to SNP-length branch lengths using the python 612 613 implementation of pyjar(71) (https://github.com/simonrharris/pyjar) as input for rPinecone(19). 614 Closely related clusters taking their phylogenetic distance into account were determined with 615 5 SNPs as cut-off for minor and 10 as cut-off for major clusters. These were visualised with iTol(72) (v6.8) with visualisation files generated as implemented in rPinecone(19). For ST35, 616 617 ST39 and ST14/15 (combining ST14 and ST15 isolates in one analysis) we performed ST-618 specific mappings of all respective isolates against references from these sequence types to gain higher resolution (CP041353.2(73), LR991401.1(74) and CP008929.1(75), resp.). 619

620

621 Pan-genome reconstruction, generation of a core gene alignment, and identification of 622 neighbouring gene regions were derived via panaroo(76) (v1.3.3) using the '-clean-mode strict' setting. The phylogenetic tree based on the core gene alignment, with informative sites 623 624 extracted with snp-sites as above, was calculated using igtree(69) (v1.6.12) and the internal 625 ModelFinder(70) function (GTR+F+ASC+G4) as above. All other metadata summary analyses 626 and visualisation were generated using the ggplot(77) and ggtree(78) packages in R(79) 627 unless indicated otherwise; some colour schemes are derived from or inspired by the 628 **MetBrewer** (https://github.com/BlakeRMills/MetBrewer) and NationalParks 629 (https://github.com/katieiolly/nationalparkcolors) R libraries. fiaures Composite were 630 generated using the patchwork package (https://github.com/thomasp85/patchwork). An 631 RMarkdown file to generate the analysis plots and the underlying tree and data files are freely 632 available online (https://github.com/EvitaH/QECHospitalKlebs; doi: 633 10.5281/zenodo.8421658).

- 634
- 635

636 Data availability

All sequence data is available on SRA/ENA under BioProject PRJEB42462; specific 637 638 accessions and all additional data is provided in the supporting tables S1-S5. All data and 639 code used to create the analyses and is available as R package QECHospitalKlebs v0.0.9 640 (https://github.com/EvitaH/QECHospitalKlebs; doi: 10.5281/zenodo.8421658).

641 642 Acknowledgments

We would like to thank the Sanger Institute Pathogen Genomics group for expert 643 644 computational support. We acknowledge and thank all the clinical staff and patients at QECH

- 645 over the years for their contribution; and the MLW core microbiology team for expert support 646 in storage and handling of the isolates.
- 647

648 Funding

- We acknowledge funding from Wellcome (EH; grant 217303/Z/19/Z) and the BMGF (NAF and 649
- 650 EH; grant INV-005180) as well as Wellcome funding providing core support for the Wellcome 651 Sanger Institute (206194) and MLW (206454). The funders had no role in study design, data
- collection and analysis, decision to publish, or preparation of the manuscript. 652
- 653

654 Ethics statement

- 655 Ethical approval for this study was granted by the University of Malawi College of Medicine Research Ethics Committee (COMREC) (P.11/18/2541) and isolates were shipped under a 656 657 Nagoya Protocol compliant Access and Benefit Sharing agreement between the Government 658 of Malawi and the Wellcome Sanger Institute.
- 659

660 **Competing interests**

- 661 The authors declare no competing interests.
- 662

Author contributions 663

- Conceptualization: EH, NAF; Methodology: EH, NAF; Software: EH, JML; Validation: EH, OP, 664 AZ; Formal analysis: EH, OP; Investigation: EH, OP, AZ, PM, PS, ET, FG, RL, SL, JC, JML; 665 Resources: SB. PS. ET. KK. NRT. NAF: Data curation: EH. OP. PM. RL. JC. JML. AZ: 666 667 Writing—original draft: EH, OP, NAF; Writing—review & editing: all authors; Visualization: EH, OP, JML, NAF; Supervision: EH, CM, SL, KK, NAF; Project administration: EH, NAF; Funding 668 669 acquisition: EH, NRT, NAF
- 670

671 **Figure legends:**

- 672 Fig 1. Kpn cases at QECH. (A) Numbers of Kpn cases per year at QECH. Bars represent the 673 crude frequency of Kpn infection for each year from 1998 - 2021, with the different colours 674 representing the different age groups of the patients. (B) Blood culture positivity rate (per 1,000 675 blood cultures) of *Kpn* in neonates and the entire patient population.
- 676 Fig 2. Uneven distribution of STs and cases at QECH wards indicate hospital-acquired 677 infections. (A) Main STs and (B) wards the samples were derived from over time. (C) A 678 schematic map of QECH with the wards samples of our study were derived from highlighted. 679 AETC – Adult emergency and Trauma Centre; Paediatric A&E – paediatric accident and 680 emergency; PICU – paediatric intensive care unit; HDU – high dependency unit.
- Fig 3. Most cases suspected to be caused by within-ward transmissions. Mapping trees 681 682 against reference genomes for (A) K. pneumoniae subsp. pneumoniae excluding STs represented with only a single isolate in the dataset, (B) K. guasipneumoniae and (C) K. 683 684 variicola. (D-E) show ST-specific mapping of the relevant isolates against references for ST35 (D), ST39 (E), ST14/ST15 (F). The coloured tips indicates isolates with <5 SNPs distance to 685 686 their nearest neighbour based on a root-to-tip approach to identify related clusters of 687 isolates(19). The colour ring in (A) shows the main STs, the columns in D-F show year of 688 isolate (left column) and major ward (right column).
- Fig 4. Resistance mechanisms only explain beta-lactam, not aminoglycoside, 689 690 phenotypes. (A) The distribution of ESBL genes over time illustrating the dominance of *bla_{CTX}*. 691 $_{M-15}$. (B) Phenotypic chloramphenicol resistance profiles proportional over time and the 692 presence or absence of catA1 and/or catA2 compared to catB4, the recently re-characterised

693 non-functional CAT enzyme. (C) and (D) Predicted aminoglycoside resistance was based on 694 the presence of an Aac6'-lb-cr or Aac6'-lb gene (AAC(6')-l) for amikacin and Aac3 IIa 695 (AAC(3)-II) or AadB (ANT(2")-I) for gentamicin. The x-axis shows the samples based on 696 phenotypic resistance profiles (intermediate, sensitive, resistant) against (C) amikacin and (D) 697 gentamicin, and the bars show number of isolates in the respective category that would have 698 been predicted as sensitive (blue) or resistant (red) based on the genes as above.

699 Fig 5. High fluctuation of putative vaccine targets over time and diversity within major

- 700 STs. The distribution of O-Ag locus types (top panels) and K-locus types (lower panels), resp.,
- 701 over time showing total numbers (A) and (D), only isolates with ESBL resistance genes (B)
- 702 and (E) or ESBL-negative isolates (C) and (F).

703

- 704 References
- 705 1. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes 706 of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 707 Sustainable Development Goals. Lancet Lond Engl. 2016 Dec 17;388(10063):3027-35.
- 2. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of 708 709 antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low-710 and middle-income countries. Nat Microbiol. 2021 Apr;6(4):512–23.
- 711 3. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, et al. Trends in 712 antimicrobial resistance in bloodstream infection isolates at a large urban hospital in 713 Malawi (1998-2016): a surveillance study. Lancet Infect Dis. 2017;17(10):1042-52.
- 714 4. Salzberg NT, Sivalogan K, Bassat Q, Taylor AW, Adedini S, El Arifeen S, et al. Mortality 715 Surveillance Methods to Identify and Characterize Deaths in Child Health and Mortality Prevention Surveillance Network Sites. Clin Infect Dis. 2019 Oct 716 717 9;69(Supplement 4):S262-73.
- 718 5. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev 719 Microbiol [Internet]. 2020 Feb 13 [cited 2020 Feb 24]; Available from: 720 http://www.nature.com/articles/s41579-019-0315-1
- 721 6. Ellington MJ, Heinz E, Wailan AM, Dorman MJ, de Goffau M, Cain AK, et al. Contrasting 722 patterns of longitudinal population dynamics and antimicrobial resistance mechanisms in 723 two priority bacterial pathogens over 7 years in a single center. Genome Biol. 2019 724 02;20(1):184.
- 725 7. Lipworth S. Vihta KD. Chau K. Barker L. George S. Kavanagh J. et al. Ten-vear 726 longitudinal molecular epidemiology study of Escherichia coli and Klebsiella species 727 bloodstream infections in Oxfordshire, UK. Genome Med. 2021 Sep 3;13(1):144.
- 728 8. Fostervold A, Hetland MAK, Bakksjø R, Bernhoff E, Holt KE, Samuelsen Ø, et al. A 729 nationwide genomic study of clinical Klebsiella pneumoniae in Norway 2001-15: 730 introduction and spread of ESBLs facilitated by clonal groups CG15 and CG307. J 731 Antimicrob Chemother. 2022 Feb 23;77(3):665-74.
- 9. Thorpe H, Booton R, Kallonen T, Gibbon MJ, Couto N, Passet V, et al. One Health or 732 Three? Transmission modelling of Klebsiella isolates reveals ecological barriers to 733 734 transmission between humans, animals and the environment [Internet]. Microbiology; 735 2021 Aug [cited 2023 May 17]. Available from:
- 736 http://biorxiv.org/lookup/doi/10.1101/2021.08.05.455249

- 737 10. Wyres KL, Nguyen TNT, Lam MMC, Judd LM, van Vinh Chau N, Dance DAB, et al. 738 Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella 739 pneumoniae from South and Southeast Asia. Genome Med. 2020 Dec;12(1):11.
- 11. World Health Organization, editor. Antimicrobial resistance: global report on surveillance. 740 741 Geneva, Switzerland: World Health Organization; 2014. 232 p.
- 12. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, Criscuolo A, Brisse S. Description 742 of Klebsiella africanensis sp. nov., Klebsiella variicola subsp. tropicalensis subsp. nov. 743 744 and Klebsiella variicola subsp. variicola subsp. nov. Res Microbiol. 2019 745 May;170(3):165-70.
- 13. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbvwinji M, Molyneux ME, et al. 746 747 Bacteraemia and mortality among adult medical admissions in Malawi--predominance of 748 non-typhi salmonellae and Streptococcus pneumoniae. J Infect. 2001 Jan;42(1):44-9.
- 749 14. Lester R, Musicha P, Kawaza K, Langton J, Mango J, Mangochi H, et al. Effect of 750 resistance to third-generation cephalosporins on morbidity and mortality from 751 bloodstream infections in Blantyre, Malawi: a prospective cohort study. Lancet Microbe. 752 2022 Dec;3(12):e922-30.
- 15. Cornick J, Musicha P, Peno C, Seager E, Iroh Tam PY, Bilima S, et al. Genomic 753 754 investigation of a suspected Klebsiella pneumoniae outbreak in a neonatal care unit in 755 sub-Saharan Africa. Microb Genomics. 2021 Nov;7(11).
- 756 16. Musicha P, Msefula CL, Mather AE, Chaguza C, Cain AK, Peno C, et al. Genomic 757 analysis of Klebsiella pneumoniae isolates from Malawi reveals acquisition of multiple 758 ESBL determinants across diverse lineages. J Antimicrob Chemother. 2019 May 759 1;74(5):1223-32.
- 17. Ejaz H, Wang N, Wilksch JJ, Page AJ, Cao H, Gujaran S, et al. Phylogenetic Analysis of 760 761 Klebsiella pneumoniae from Hospitalized Children, Pakistan. Emerg Infect Dis. 2017 762 Nov;23(11):1872–5.
- 18. Chung The H, Karkey A, Pham Thanh D, Boinett CJ, Cain AK, Ellington M, et al. A high-763 764 resolution genomic analysis of multidrug-resistant hospital outbreaks of Klebsiella 765 pneumoniae. EMBO Mol Med. 2015 Mar;7(3):227-39.
- 19. Wailan AM, Coll F, Heinz E, Tonkin-Hill G, Corander J, Feasey NA, et al. rPinecone: 766 767 Define sub-lineages of a clonal expansion via a phylogenetic tree. Microb Genomics. 768 2019;5(4).
- 769 20. Gorrie CL, Da Silva AG, Ingle DJ, Higgs C, Seemann T, Stinear TP, et al. Key 770 parameters for genomics-based real-time detection and tracking of multidrug-resistant 771 bacteria: a systematic analysis. Lancet Microbe. 2021 Nov;2(11):e575-83.
- 21. Mangochi H, Tolhurst R, Simpson V, Kawaza K, Chidziwisano K, Feasey NA, et al. A 772 773 qualitative study exploring hand hygiene practices in a neonatal unit in Blantyre, Malawi: 774 implications for controlling healthcare-associated infections. Wellcome Open Res. 775 2022;7:146.
- 22. Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena 776 777 ZR, Hernández-Torres A, et al. Effectiveness of Fosfomycin for the Treatment of 778 Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized 779 Clinical Trial. JAMA Netw Open. 2022 Jan 13;5(1):e2137277.

- 780 23. McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality 781 imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013 782 May;41(5):463-7.
- 24. Veleba M, Schneiders T. Tigecycline Resistance Can Occur Independently of the ramA 783 784 Gene in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012 Aug;56(8):4466-7.
- 25. Zhang R, Dong N, Huang Y, Zhou H, Xie M, Chan EWC, et al. Evolution of tigecycline-785 786 and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and 787 its persistence in the GI tract. Emerg Microbes Infect. 2018 Jul 9;7(1):127.
- 788 26. Roy S, Datta S, Viswanathan R, Singh AK, Basu S. Tigecycline susceptibility in 789 Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and 790 role of an efflux pump in tigecycline non-susceptibility. J Antimicrob Chemother. 2013 791 May;68(5):1036-42.
- 792 27. He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, et al. Emergence of plasmid-mediated 793 high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019 794 Sep;4(9):1450-6.
- 795 28. Huang Y, Rana AP, Wenzler E, Ozer EA, Krapp F, Bulitta JB, et al. Aminoglycoside-796 resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-797 resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2022 Feb 2:77(2):356-63.
- 798 29. Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, et al. The diversity of 799 Klebsiella pneumoniae surface polysaccharides. Microb Genomics. 2016;2(8):e000073.
- 30. Kelly SD, Ovchinnikova OG, Müller F, Steffen M, Braun M, Sweeney RP, et al. 800 801 Identification of a second glycoform of the clinically prevalent O1 antigen from Klebsiella 802 pneumoniae. Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2301302120.
- 803 31. Lam MMC, Wick RR, Judd LM, Holt KE, Wyres KL. Kaptive 2.0: updated capsule and 804 lipopolysaccharide locus typing for the Klebsiella pneumoniae species complex. Microb 805 Genomics [Internet]. 2022 Mar 21 [cited 2023 Jul 20];8(3). Available from: 806 https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000800
- 807 32. Orskov I, Fife-Asbury MA. New Klebsiella Capsular Antigen, K82, and the Deletion of 808 Five of Those Previously Assigned. Int J Syst Bacteriol. 1977 Oct 1;27(4):386-7.
- 33. Edmunds PN. Further Klebsiella Capsule Types. J Infect Dis. 1954 Jan 1;94(1):65-71. 809
- 810 34. Edwards PR, Fife MA. Capsule Types of Klebsiella. J Infect Dis. 1952 Jul 1;91(1):92-811 104.
- 812 35. Lewis JM, Mphasa M, Banda R, Beale MA, Heinz E, Mallewa J, et al. Colonization 813 dynamics of extended-spectrum beta-lactamase-producing Enterobacterales in the gut of Malawian adults. Nat Microbiol. 2022 Oct;7(10):1593-604. 814
- 815 36. Lewis JM, Mphasa M, Banda R, Beale MA, Mallewa J, Heinz E, et al. Genomic and 816 antigenic diversity of colonizing Klebsiella pneumoniae isolates mirrors that of invasive isolates in Blantyre, Malawi. Microb Genomics. 2022 Mar;8(3):000778. 817
- 818 37. Feasey NA, Houston A, Mukaka M, Komrower D, Mwalukomo T, Tenthani L, et al. A 819 Reduction in Adult Blood Stream Infection and Case Fatality at a Large African Hospital

- following Antiretroviral Therapy Roll-Out. Pett S, editor. PLoS ONE. 2014 Mar
 18;9(3):e92226.
- 38. Lewis JM, Lester R, Mphasa M, Banda R, Edwards T, Thomson NR, et al. Emergence of
 carbapenemase-producing Enterobacteriaceae in Malawi. J Glob Antimicrob Resist.
 2020 Mar;20:225–7.
- 825 39. Kumwenda GP, Sugawara Y, Abe R, Akeda Y, Kasambara W, Chizani K, et al. First
 826 Identification and genomic characterization of multidrug-resistant carbapenemase827 producing Enterobacteriaceae clinical isolates in Malawi, Africa. J Med Microbiol. 2019
 828 Dec 1;68(12):1707–15.
- 40. Zhang F, Li Q, Bai J, Ding M, Yan X, Wang G, et al. Heteroresistance to Amikacin in
 Carbapenem-Resistant Klebsiella pneumoniae Strains. Front Microbiol. 2021;12:682239.
- 41. Mankhomwa J, Tolhurst R, M'biya E, Chikowe I, Banda P, Mussa J, et al. A Qualitative
 Study of Antibiotic Use Practices in Intensive Small-Scale Farming in Urban and PeriUrban Blantyre, Malawi: Implications for Antimicrobial Resistance. Front Vet Sci. 2022
 May 24;9:876513.
- 42. Darlow CA, Farrington N, Johnson A, McEntee L, Unsworth J, Jimenez-Valverde A, et
 al. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the
 setting of highly prevalent antimicrobial resistance. J Antimicrob Chemother. 2022 Apr
 27;77(5):1334–43.
- 43. Lipworth S, Vihta KD, Chau KK, Kavanagh J, Davies T, George S, et al. Ten Years of
 Population-Level Genomic *Escherichia coli* and *Klebsiella pneumoniae* Serotype
 Surveillance Informs Vaccine Development for Invasive Infections. Clin Infect Dis. 2021
 Dec 16;73(12):2276–82.
- 44. Heinz E, Ejaz H, Bartholdson Scott J, Wang N, Gujaran S, Pickard D, et al. Resistance
 mechanisms and population structure of highly drug resistant Klebsiella in Pakistan
 during the introduction of the carbapenemase NDM-1. Sci Rep. 2019 Dec;9(1):2392.
- 45. Heinz E, Brindle R, Morgan-McCalla A, Peters K, Thomson NR. Caribbean multi-centre study of Klebsiella pneumoniae: whole-genome sequencing, antimicrobial resistance and virulence factors. Microb Genomics [Internet]. 2019 May 1 [cited 2020 Feb 24];5(5).
 Available from:
- 850 https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000266
- 46. Wantuch PL, Knoot CJ, Robinson LS, Vinogradov E, Scott NE, Harding CM, et al.
 Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and
 function across both classical and hypervirulent K2:O1 strains of Klebsiella pneumoniae.
 Hakansson AP, editor. PLOS Pathog. 2023 May 5;19(5):e1011367.
- 47. Loraine J, Heinz E, De Sousa Almeida J, Milevskyy O, Voravuthikunchai SP, Srimanote
 P, et al. Complement Susceptibility in Relation to Genome Sequence of Recent
 Klebsiella pneumoniae Isolates from Thai Hospitals. mSphere. 2018 07;3(6).
- 48. Kol O, Wieruszeski JM, Strecker G, Fournet B, Zalisz R, Smets P. Structure of the Ospecific polysaccharide chain of Klebsiella pneumoniae O1K2 (NCTC 5055)
 lipopolysaccharide. A complementary elucidation. Carbohydr Res. 1992 Dec
 15;236:339–44.

- 862 49. Whitfield C, Richards JC, Perry MB, Clarke BR, MacLean LL. Expression of two structurally distinct D-galactan O antigens in the lipopolysaccharide of Klebsiella 863 864 pneumoniae serotype O1. J Bacteriol. 1991 Feb;173(4):1420-31.
- 50. Kol O, Wieruszeski JM, Strecker G, Montreuil J, Fournet B, Zalisz R, et al. Structure of 865 866 the O-specific polysaccharide chain from Klebsiella pneumoniae O1K2 (NCTC 5055) 867 lipopolysaccharide. Carbohydr Res. 1991 Sep 18:217:117-25.
- 51. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using 868 869 exact alignments. Genome Biol. 2014 Mar 3;15(3):R46.
- 870 52. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a 871 new genome assembly algorithm and its applications to single-cell sequencing. J 872 Comput Biol J Comput Mol Cell Biol. 2012 May;19(5):455-77.
- 53. Page AJ, De Silva N, Hunt M, Quail MA, Parkhill J, Harris SR, et al. Robust high-873 874 throughput prokaryote de novo assembly and improvement pipeline for Illumina data. 875 Microb Genomics. 2016;2(8):e000083.
- 876 54. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinforma Oxf Engl. 2014 877 Jul 15;30(14):2068–9.
- 878 55. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: rapid 879 antimicrobial resistance genotyping directly from sequencing reads. Microb Genomics. 880 2017;3(10):e000131.
- 56. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid 881 882 genomic surveillance for public health and hospital microbiology labs. Genome Med. 2014;6(11):90. 883
- 884 57. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al. 885 ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in 886 bacterial genomes. Antimicrob Agents Chemother. 2014;58(1):212-20.
- 887 58. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The 888 comprehensive antibiotic resistance database. Antimicrob Agents Chemother. 2013 889 Jul;57(7):3348–57.
- 890 59. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In 891 silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus 892 sequence typing. Antimicrob Agents Chemother. 2014 Jul;58(7):3895–903.
- 60. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic 893 894 surveillance framework and genotyping tool for Klebsiella pneumoniae and its related 895 species complex. Nat Commun. 2021 Jul 7;12(1):4188.
- 896 61. Wick RR, Heinz E, Holt KE, Wyres KL. Kaptive Web: User-Friendly Capsule and 897 Lipopolysaccharide Serotype Prediction for Klebsiella Genomes. Diekema DJ, editor. J 898 Clin Microbiol. 2018 Apr 4;56(6):e00197-18, /jcm/56/6/e00197-18.atom.
- 899 62. Torsten Seemann. snippy: fast bacterial variant calling from NGS reads [Internet]. 900 Available from: https://github.com/tseemann/snippy

- 901 63. Wu KM, Li LH, Yan JJ, Tsao N, Liao TL, Tsai HC, et al. Genome sequencing and 902 comparative analysis of Klebsiella pneumoniae NTUH-K2044, a strain causing liver 903 abscess and meningitis. J Bacteriol. 2009 Jul;191(14):4492–501.
- 904 64. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid 905 phylogenetic analysis of large samples of recombinant bacterial whole genome 906 sequences using Gubbins. Nucleic Acids Res. 2015 Feb 18:43(3):e15-e15.
- 907 65. Price MN, Dehal PS, Arkin AP. FastTree: Computing Large Minimum Evolution Trees 908 with Profiles instead of a Distance Matrix. Mol Biol Evol. 2009 Jul 1;26(7):1641–50.
- 909 66. Elliott AG, Ganesamoorthy D, Coin L, Cooper MA, Cao MD. Complete Genome 910 Sequence of Klebsiella quasipneumoniae subsp. similipneumoniae Strain ATCC 911 700603. Genome Announc. 2016 May 26;4(3):e00438-16.
- 67. Pinto-Tomás AA, Anderson MA, Suen G, Stevenson DM, Chu FST, Cleland WW, et al. 912 913 Symbiotic nitrogen fixation in the fungus gardens of leaf-cutter ants. Science. 2009 Nov 914 20;326(5956):1120-3.
- 915 68. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid 916 efficient extraction of SNPs from multi-FASTA alignments. Microb Genomics. 917 2016;2(4):e000056.
- 918 69. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective 919 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. Mol Biol Evol. 920 2015 Jan;32(1):268-74.
- 921 70. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017 922 923 Jun;14(6):587-9.
- 924 71. Pupko T, Pe'er I, Shamir R, Graur D. A fast algorithm for joint reconstruction of ancestral 925 amino acid sequences. Mol Biol Evol. 2000 Jun;17(6):890-6.
- 926 72. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree 927 display and annotation. Nucleic Acids Res. 2021 Jul 2;49(W1):W293-6.
- 928 73. Shen Z, Gao Q, Qin J, Liu Y, Li M. Emergence of an NDM-5-Producing Hypervirulent 929 Klebsiella pneumoniae Sequence Type 35 Strain with Chromosomal Integration of an 930 Integrative and Conjugative Element, ICE Kp1. Antimicrob Agents Chemother. 2019 Dec. 931 20;64(1):e01675-19.
- 74. Cabanel N, Rosinski-Chupin I, Chiarelli A, Botin T, Tato M, Canton R, et al. Evolution of 932 933 VIM-1-Producing Klebsiella pneumoniae Isolates from a Hospital Outbreak Reveals the 934 Genetic Bases of the Loss of the Urease-Positive Identification Character. Beiko RG, 935 editor. mSystems. 2021 Jun 29;6(3):e00244-21.
- 75. Stoesser N, Giess A, Batty EM, Sheppard AE, Walker AS, Wilson DJ, et al. Genome 936 937 sequencing of an extended series of NDM-producing Klebsiella pneumoniae isolates 938 from neonatal infections in a Nepali hospital characterizes the extent of community-939 versus hospital-associated transmission in an endemic setting. Antimicrob Agents 940 Chemother. 2014 Dec;58(12):7347-57.

- 76. Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, Lees JA, et al. Producing
 polished prokaryotic pangenomes with the Panaroo pipeline. Genome Biol. 2020
 Dec;21(1):180.
- 944 77. Wickham H. Ggplot2: elegant graphics for data analysis. New York: Springer; 2009. 212
 945 p. (Use R!).
- 78. Yu G, Lam TTY, Zhu H, Guan Y. Two Methods for Mapping and Visualizing Associated
 Data on Phylogeny Using Ggtree. Mol Biol Evol. 2018 01;35(12):3041–3.
- 948 79. R Core Team. A Language and Environment for Statistical Computing [Internet]. R
 949 Foundation for Statistical Computing, Vienna.; 2021. Available from: https://www.R 950 project.org

951





Ĭ

Ē



Figure 3







